Table 1.
Baseline characteristics of patients grouped by CT or ET.
| Characteristics | Endocrine therapy N = 31 n (%) | Chemotherapy N = 100 n (%) | P values |
|---|---|---|---|
| Median Age | 58 | 58 | 0.77 |
| (range) | (40–75) | (33–85) | |
| Menopausal status | |||
| Postmenopausal | 29 (93.5) | 95 (95) | 0.754 |
| Premenopausal | 2 (6.5) | 5 (5) | |
| DFI | |||
| <2 years | 4 (12.9) | 21 (21) | 0.593 |
| ≥2 years | 25 (80.6) | 74 (74) | |
| de novo stage IV breast cancer | 2 (6.5) | 5 (5) | |
| ECOG score | |||
| 0–1 | 30 (100) | 97 (97) | 0.631 |
| ≥2 | 0 | 3 (3) | |
| Number of metastatic sites | |||
| 1 | 9 (29) | 33 (33) | 0.94 |
| 2 | 12 (38.7) | 32 (32) | |
| ≥3 | 10 (32.2) | 34 (34) | |
| Metastatic sites | |||
| Visceral | 17 (54.8) | 51 (51) | 0.709 |
| Liver | 10 (32.3) | 18 (18) | 0.13 |
| Lung | 12 (38.7) | 41 (41) | 0.82 |
| Bone | 19 (61.3) | 63 (63) | 0.864 |
| Line of Ful | |||
| 1 | 15 (48.4) | 46 (46) | 0.723 |
| 2 | 16 (51.6) | 54 (54) | |
| Ful PFS | |||
| ≥6 months | 17 (54.8) | 45 (45) | 0.338 |
| <6 months | 14 (45.2) | 55 (55) | |
| Previous ET | |||
| Tamoxifen | 15 (48.4) | 50 (50) | 0.875 |
| NSAI | 14 (45.2) | 54 (54) | 0.389 |
| SAI | 7 (22.6) | 24 (24) | 0.87 |